{"anticipatedPostingDate":"2026-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.20","value":"-0.15"},{"groupId":"OG001","spread":"0.21","value":"-0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"End of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"-0.02"},{"groupId":"OG001","spread":"0.18","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"3 months from end of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.00"},{"groupId":"OG001","spread":"0.15","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"6 months from end of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.03"},{"groupId":"OG001","spread":"0.18","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"12 months from end of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"description":"The EQ-5D-3L index score measures health-related quality of life using five items (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with three levels of severity (1 = no problems, 2 = moderate problems, 3 = extreme problems). Responses across the five items are combined and transformed into a single utility (index) score. Possible scores range from 0 to 1, with higher scores indicating a better outcome. The change score was calculated as the postbaseline value minus the baseline value. A negative change reflects decline at the postbaseline timepoint and a positive change reflects improvement at the postbaseline timepoint.","dispersionType":"Standard Error","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"MEAN","populationDescription":"Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data at baseline and at least one postbaseline timepoint.","reportingStatus":"POSTED","timeFrame":"Basline, end of treatment (6-7 weeks), and 3, 6, and 12 months from end of treatment.","title":"EuroQol Five Dimension Scale 3-level Version (EQ-5D-3L) Index Score Change From Baseline","type":"SECONDARY","unitOfMeasure":"score on a scale"}